Home › Companies › IMUX

Immunic

IMUX Lead: Phase 3 1 Biotech Distilled article ↓

GI/Hepatology Neurology Small Molecule

Most recent annual filing: 2026-02-26

Pipeline (4 active programs)

vidofludimus calcium

IMU-838

Small Molecule Target: DHODH, Nurr1

Relapsing Multiple Sclerosis Phase 3 oral
Progressive Multiple Sclerosis Phase 2 oral

IMU-856

Small Molecule Target: SIRT6

Celiac Disease Phase 1 oral

IMU-381

Small Molecule Target: Nurr1

Undisclosed indication Preclinical oral

Technology platforms

Nurr1 platform

Nuclear receptor-related 1 (Nurr1) activation platform comprising next-generation small molecule derivatives (IMU-381 series) targeting neurologic, gastrointestinal, and autoimmune diseases

Targets: Nurr1

Biotech Distilled coverage (1)

2026-05-28 Immunic, Inc. (IMUX) — Scientific Deep Dive for Vidofludimus Calcium (IMU-838) and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.